Alemtuzumab improved outcomes versus subcutaneous interferon (SC IFN)β-1a over 2 years in multiple sclerosis (MS) patients with highly active disease from CARE-MS and extension studies. Efficacy was maintained up to 9 years . Safety data of alemtuzumab was also presented, notably acute adverse events (AEs) during infusion and in the days following, as well as AEs occurring after lymphocyte repopulation.
Alemtuzumab efficacy and safety over 9 years were reported in patients that were previously treated with disease-modifying treatment and with highly active disease at baseline of the core CARE-MS I/II trials. In the first 2 years, annualised relapse rate was decreased with alemtuzumab versus SC IFNβ-1a and remained low in years 3-9 (0.16, 0.17, and 0.25, respectively, according to definition). Through year 9, 49%-59% of patients with highly active disease achieved 6-month confirmed disability ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Results of compounds in late stages of development Next Article
Fampridine treatment results in routine clinical practice »
Table of Contents: EAN 2020
Headache and Pain
Neuromyelitis Optica Spectrum Disorder
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.